Granted Patent B2

US 12,329,862 · App. 17/250,162 · Granted Jun 17, 2025

Inventors: Patrick Mohr (Bad Breisig, DE); René Rietscher (Neuwied, DE); René Eifler (Koblenz, DE); Olga Bourquain (Dürrholz, DE)

Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

A61K9/7061A61K31/407

Abstract

Claims (53)

1. A transdermal therapeutic system for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, said self-adhesive layer structure comprising:

A) a backing layer;

B) an asenapine-containing matrix layer comprising:

a) asenapine;

b) a polymer selected from acrylic polymers; and

c) medium chain triglycerides in an amount of from 5 to 12% of the matrix layer, wherein the fatty acid composition of the medium chain triglycerides

have a fatty acid composition according to one of:

(i) 0 to 5% hexanoic acid,

(ii) 40.0 to 90.0% octanoic acid,

(iii) 10.0 to 55.0% decanoic acid,

(iv) 0 to 5% dodecanoic acid, and

(v) 0 to 2% tetradecanoic acid;

(i) 0 to 2% hexanoic acid,

(ii) 50.0 to 80.0% octanoic acid,

(iii) 20.0 to 45.0% decanoic acid,

(iv) 0 to 2% dodecanoic acid, and

(v) 0 to 1% tetradecanoic acid;

(i) 0 to 2% hexanoic acid,

(ii) 50.0 to 65.0% octanoic acid,

(iii) 30.0 to 45.0% decanoic acid,

(iv) 0 to 2% dodecanoic acid, and

(v) 0 to 1% tetradecanoic acid;

or

(i) 0 to 2% hexanoic acid,

(ii) 65.0 to 80.0% octanoic acid,

(iii) 20.0 to 35.0% decanoic acid,

(iv) 0 to 2% dodecanoic acid, and

(v) 0 to 1% tetradecanoic acid

wherein the transdermal therapeutic system contains from 0.82 mg/cm 2 to 2.0 mg/cm 2 asenapine and wherein the transdermal therapeutic system comprises a synergistic amount of ascorbyl palmitate and α-tocopherol.

2. The transdermal therapeutic system according to claim 1 , wherein the matrix layer comprises the medium chain triglycerides in an amount of at about 10% by weight.

3. The transdermal therapeutic system according to claim 1 , wherein the medium chain triglycerides have an acid value of 0.5 mg KOH/g or less.

4. The transdermal therapeutic system according to claim 1 , wherein the asenapine in the matrix layer is included in the form of asenapine free base.

5. The transdermal therapeutic system according to claim 1 , wherein the matrix layer comprises at least 90 mol % asenapine free base, at least 95 mol % asenapine free base, at least 98 mol % asenapine free base, or at least 99 mol % asenapine free base, based on the amount of asenapine in the matrix layer.

6. The transdermal therapeutic system according to claim 1 , wherein the matrix layer comprises from 2 to 20% asenapine by weight, from 3 to 15% asenapine by weight, or from 4 to 12% asenapine by weight.

7. The transdermal therapeutic system according to claim 1 , wherein the polymer is selected from the group consisting of pressure-sensitive adhesive polymers; acrylic polymers comprising hydroxyl groups and no carboxylic acid groups; a copolymer of vinyl acetate, 2-ethylhexyl-acrylate, 2-hydroxyethyl-acrylate, and glycidyl-methacrylate; and a copolymer of vinyl acetate, 2-ethylhexyl-acrylate, and 2-hydroxyethyl-acrylate.

8. The transdermal therapeutic system according to claim 7 , wherein the polymer is cross-linked by an aluminum cross-linking agent, a titanium cross-linking agent, or an aluminum and a titanium cross-linking agent.

9. The transdermal therapeutic system according to claim 1 , wherein the matrix layer comprises from 50 to 90% polymer by weight, from 60 to 85% polymer by weight, or from 65 to 80% polymer by weight.

10. The transdermal therapeutic system according to claim 1 , wherein the matrix layer comprises an additional polymer, and wherein the additional polymer is selected from the group consisting of polyvinylpyrrolidones and soluble polyvinylpyrrolidones, and wherein the matrix layer comprises a detectable amount of the additional polymer to 20% of the additional polymer by weight, from 5 to 15% of the additional polymer by weight, or about 10% of the additional polymer by weight.

11. The transdermal therapeutic system according to claim 1 , wherein the matrix layer further comprises from 0.01 to 2% α-tocopherol by weight, or at least 0.025% α-tocopherol by weight.

12. The transdermal therapeutic system according to claim 1 , wherein the transdermal therapeutic system provides a skin permeation rate of asenapine as measured in a Franz diffusion cell with dermatomed human skin of

0 μg/(cm 2 h) to 10 μg/(cm 2 h) in the first 8 hours,

2 μg/(cm 2 h) to 20 μg/(cm 2 h) from hour 8 to hour 24,

3 μg/(cm 2 h) to 20 μg/(cm 2 h) from hour 24 to hour 32,

3 μg/(cm 2 h) to 20 μg/(cm 2 h) from hour 32 to hour 48, and

2 μg/(cm 2 h) to 15 μg/(cm 2 h) from hour 48 to hour 72.

13. A method of treating psychosis, or one or more conditions selected from the group consisting of schizophrenia, bipolar disorder, posttraumatic stress disorder, major depressive disorder, dementia related psychosis, agitation and manic disorder, and acute manic or mixed episodes of bipolar disorder in a human patient, the method comprising applying the transdermal therapeutic system according to claim 1 to the skin of a patient in need thereof.

14. A process of manufacturing the asenapine-containing matrix layer of claim 1 , the process comprising the steps of:

a) combining at least asenapine, a polymer, and medium chain triglycerides, in a solvent to obtain a coating composition;

b) coating the coating composition onto a backing layer or a release liner, or any intermediate liner; and

c) drying the coated coating composition to form the asenapine-containing matrix layer.

15. The transdermal therapeutic system according to claim 1 , wherein the medium chain triglycerides have a peroxide value of 5.0 mequi O/kg or less, 2.0 mequi O/kg or less, or 1.0 mequi O/kg or less.

16. The transdermal therapeutic system according to claim 1 , wherein the medium chain triglycerides have a hydroxyl value of 10 mg KOH/g or less.

17. The transdermal therapeutic system according to claim 1 , wherein the matrix layer comprises at least 0.01% ascorbyl palmitate by weight.

Assignments (1)

Priority Claims (1)

Continuity (1)

References Cited (400)